Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin-Reference-Cited by-同舟云学术

Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin

Published:2012-06-29 Issue:2 Volume:56 Page:567-575
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Jacobson Ira M.,Marcellin Patrick,Zeuzem Stefan,Sulkowski Mark S.,Esteban Rafael,Poordad Fred,Bruno Savino,Burroughs Margaret H.,Pedicone Lisa D.,Boparai Navdeep,Deng Weiping,DiNubile Mark J.,Gottesdiener Keith M.,Brass Clifford A.,Albrecht Janice K.,Bronowicki Jean-Pierre

Publisher

Wiley

Subject

Hepatology

Reference20 articles.

1. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial;Manns;Lancet,2001

2. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection;Fried;N Engl J Med,2002

3. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose;Hadziyannis;Ann Intern Med,2004

4. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3;Shiffman;N Engl J Med,2007

5. Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin;Mangia;Aliment Pharmacol Ther,2010

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current therapeutics against HCV;VirusDisease;2021-06

2. Optimal stopping for response-guided dosing;Networks & Heterogeneous Media;2019

3. The Evolution of Clinical Trials for Hepatitis C;Topics in Medicinal Chemistry;2019

4. Recent Advances in Antiviral Therapy for Chronic Hepatitis C;Mediators of Inflammation;2016

5. On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial;Antiviral Therapy;2016